

09-05-06
10/762,159 12W
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle, William

Serial No.: 10/762,159


Group Art Unit No.: 1647

Filed: January 20, 2004

Examiner: Deberry, Regina M.

For: Osteoprotegerin

DocRet No.: A-378CIP2C5



INFORMATION DISCLOSURE STATEMENT

Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicant submits a copy of each of the references listed on the attached supplemental PTO-1449 Modified form for consideration by the Examiner.


Applicant makes no determination of relevancy with respect to the references submitted herewith and requests the Examiner to make an independent determination of relevance and/or materiality of the references.

Applicant, by the undersigned attorney/agent, certifies that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicant requests consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,


Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: August 31, 2006

Please send all future correspondence to:
U.S. Patent Operations/RBW
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive

EXPRESS MAIL CERTIFICATE

Express Mail label number:

EL 732825581 US

Date of Deposit:

August 31, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Printed Name


Signature

Modified Form PTO-1449		Atty. Docket No. A-3782C5	Serial No. 10/762,159
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Boyle, William	
		Filing Date 01-20-2004	Group 1647



U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	B1	WO 94/21670	Sep 29, 1994	PCT				
	B2							
	B3							
	B4							

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Garcia et al., "Transgenic Mice Expressing High Levels of Soluble TNF-R1 Fusion Protein and Protected from Lethal Septic Shock and Cerebral Malaria, and are Highly Sensitive to <i>Listeria Monocytogens</i> and <i>Leishmania Major</i> Infections", <i>European Journal of Immunology</i> , 25, 2401-2407 (1995).
	C2	Himmeler et al., "Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein", <i>DNA and Cell Biology</i> , 9(10), 705-715 (1990).
	C3	
	C4	
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	

EXAMINER:	Date Considered:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.